- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -  - Selective JAK V617F inhibitor, CGT1145, on track for IND

COGT

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Cogent's CGT1145 advances JAK2 V617F program with 2026 IND target

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -  - Selective JAK V617F inhibitor, CGT1145, on track for IND</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cogent presented CGT1145 preclinical data at EHA, highlighting &gt;100x selectivity over JAK2 WT and JAK1/3, plus strong oral bioavailability. The company aims for IND in 2026, signaling a potential disease-modifying JAK2 therapy for MPNs with better tolerability. Clinical proof remains years away, so risk remains high.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Cogent reports CGT1145 preclinical data at EHA. IND planned for 2026.</li><li>CGT1145 shows &gt;100x selectivity vs JAK2 WT and JAK1/3; oral bioavailability.</li><li>IND filing targeted for 2026; EHA poster highlights potential best-in-class properties.</li><li>JAK2 V617F drives most MPNs; CGT1145 aims for molecular remission with tolerability.</li><li>CEO says CGT1145 is rapidly advancing; data posted on Cogent&#039;s site.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cogent Biosciences, Inc. (COGT)</strong>: Announced preclinical CGT1145 data; IND planned in 2026; EHA poster highlights best-in-class potential.</li><li><strong>Incyte Corporation (INCY)</strong>: Major JAK inhibitor footprint with Jakafi; potential competitive pressure in JAK2-targeted therapies.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News; reflects Cogent&#039;s R&amp;D progress and near-term regulatory milestones driving company-relevant sentiment.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>EHA data and 2026 IND target could spark speculative upside for COGT.</li><li>No clinical data yet; milestones could cause volatility.</li><li>CGT1145 &gt;100x selectivity may attract JAK2-focused investors.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>CGT1145 is a JAK2 V617F mutant-selective inhibitor; preclinical data presented at EHA 2026.</li><li>CGT1145 shows &gt;100x selectivity over JAK2 WT and JAK1/3.</li><li>IND filing targeted for 2026.</li><li>JAK2 V617F mutation prevalent in ~95% of polycythemia vera (PV) and ~50% of primary myelofibrosis (PMF) or essential thrombocythemia (ET).</li><li>EHA Congress dates: June 11-14, 2026, in Stockholm.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Long-term bullish; IND in 2026 could unlock value if data translates to humans.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center"><em>- </em><em>JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -</em></p>  <p align="center"><em>- Selective JAK V617F inhibitor, CGT1145, on track for IND in 2026 -</em></p>    <p>WALTHAM, Mass. and BOULDER, Colo., June  12, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Pr-QZQR4FPQSgV7b2ZdehbbRsc52cMxiIVLU_hNNRPlp--sv8hCWh8E7-PtX2rkXPWZtAibARhswl2F-XMnWX3rHfVQbMvhn8bjEkiquMXgIvqSfYy0Ec6UQj_6xLXOLh25zMF32glLSVE7VEsqdYvYKzt7kg6WB42ETdld8d6Xhvq9JmpI1ugpyqWa8Xr10VSnHQf1Z8kQGHWwVEwwxR6-ZYeGGHw0qCShYJ29YzTMyGaH0BLsSMUSTTuIXVu6mrmfk17LC5DPx5Jg7cNYlOg==" rel="nofollow" target="_blank"><u>Cogent Biosciences, Inc.</u></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COGT">COGT</a>), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from its novel, potential best-in-class JAK2 V617F mutant-selective inhibitor in a poster presentation at the 2026 European Hematology Association (EHA) Congress taking place in Stockholm, Sweden, June 11-14, 2026.</p>    <p>"We're encouraged by the preclinical data from our next-generation JAK2 program being presented at EHA today," said Andrew Robbins, Cogent's President and Chief Executive Officer. "This highly selective, potent inhibitor of JAK2 V617F has the potential to address the underlying mutational driver of disease while mitigating off-target hematological effects. We are rapidly advancing this program and remain on track to submit our Investigational New Drug application in 2026."</p>    <p>JAK2 V617F is the most prevalent molecular abnormality in BCR-ABL-negative myeloproliferative neoplasms (MPNs), occurring in approximately 95% of patients with polycythemia vera and 50% of patients with primary myelofibrosis or essential thrombocythemia. The poster highlights CGT1145, a potent inhibitor of the JAK2 V617F mutation with &gt;100x selectivity over JAK2 WT and the JAK1/3 isoforms, along with high oral bioavailability and low clearance across species. CGT1145 has the potential to eradicate JAK2 V617F myeloproliferative neoplasm propagating cells and induce molecular remission with improved hematologic tolerability.</p>    <p>Cogent's EHA posters and presentation will be available on the company's website at: <a href="https://www.globenewswire.com/Tracker?data=bMeH3czzid8kF4OD1cVLWCIWaoZQoG7tD1u8SnOc5j8lJhN7j8ShDnoa5erfElKfuwftRZZgaSvN6c6syzHhrN2LZgSUvmAamFowHEATXgKq_Zu1zKCHV0Hi_Ul7R2o1m-ZRodwMPojQolMUBlLzzmGxuQ2aHIo5VzRNPz1LwrzfS0w3BI9ZkVCGJ3V0wTUlJhd2TINeK5LvEgO4J2MXZLa25e-0m0plBtWI-8u5EBA=" rel="nofollow" target="_blank">https://www.cogentbio.com/pipeline-publications/#posters-publications</a></p>    <p><strong>About Cogent Biosciences, Inc.</strong> <br></br>Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Ka, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at <a href="http://www.cogentbio.com" title="www.cogentbio.com">www.cogentbio.com</a>. Follow Cogent Biosciences on social media: <a href="https://www.globenewswire.com/Tracker?data=46g3DkW0LJJA-JdQ9djC4TIUm2kwiWVg8HZbtoDD6sH9N0G950ZiaxofiomC3FF4Eseb7BL3uIc-ram6-ivF057WCvgs08Yc2XhlErYg3MbQqx6Pp4pjYrgwcalYMPSJPvz3esSkU7e5xyAvxejlIeljeSF95-TO7xhubITsv0YcoPFEjpdKrtRtK8p2b7HbglvhLSfVbhg7QTUn6W53DJ9pN6eGLAXBX6f-_eGeLRofPwJ0_SqzzyW2lx7Xam1B45GxTTuQJIvSW85bbCX8eTgapmUIpvOOnoO4kNFvkPvyGvdQhZv7L6mhRjvMKKWDODrZV6RdPM3N3RiJcjO7jycilUwReYqA4cM8P10WglhDq7VdURz-KD5G_oCcrkPDUF2DX7y6Eq6ohP5BbIjwEGmZKRcArUWXiwgzBPYLpZeglFI0qHSVx-3CD8ju38MGpHu5nuEmZsrIbdJmnjck2H3H2OfNmvIlOyFmPoeZpYLBkdlWy2VdhDc6htD4Pr6ye9jBa0pjY8VT-zttb53xSoh8X3vBE1VFcqc3agsSaeU_zIb2LGqNV4cotioK4JgUUhhp9_CpbTDwqwwXuYWbLRiB-zCb7EuWgmeDjeBvUOmA92sdezby_fxqd6JCKNh0Q4LCLSYjQ376M-eevHVLduxIylXAisLxD5X0O3jH_MMnHhNdueu9MzuFmi1PQ8xg" rel="nofollow" target="_blank">X</a> and <a href="https://www.globenewswire.com/Tracker?data=q_4-JYApnZgftpSKlaXiyF7m0BjEx6u-P4sNbmbOKU3g1kj27Gr7423LPQhSKD_f1Ni4N5EsMCnePbqIocOoTC8ZSBza5QY-syM07GppAOJcex_WXJrAS4HLS6zAvlbbdbMYaH9E_gJRofEtIzuaFOB-2fNNQtxe6qln0y_JQwmqf831rJYR7Ial7XGt66xI8yWc5mBFi4bviaFIPb9SijJH_h09Fku0-cKM2-oF1kDpmxu4TkWABlSS7KrCUQuIvliuS9YzjDB0KORVcdtejA==" rel="nofollow" target="_blank">LinkedIn</a>. Information that may be important to investors will be routinely posted on our website and <a href="https://www.globenewswire.com/Tracker?data=ODHMIbCBxx5hMe-4sdDL6L-XdXWyIbWQzWbuGSrsrRsP9ifsIw57QgPUiBqevr_iZ6p5Pbk1ABFhV7PiDNICj7Den9Zb6DT1RrLqNK9dMBy5FNx6mUgl9j4YKFV9WYTTmZvUzeFwO5PoXxBSPQcmOws4jfPKpFKoXt-u5LgD-jWlNT9DSHVmqEzk_XUOkCnXDYxmJ-gWunfg2rYF-NImFJxFkoiJFCRnPSLFdj2EjkSkcxPYvONLogKU1AIgF0hRlceb0D9cL5c-MkJCYlOmaetdC-P7lQ2FYanqVnq7szrLxNnwM0qM89d6RNZSn3L2MGkM-dgnUVwzfLn6jEdTXt3aQXgkgyQ4unhsNN5VshED38RdbUal_KCmMzf86uzC1KOTZuzzADUNzaYZ3xcTpJEGxbTzSEDaE3d9xX2LvyrHfKFI_WSyK9887LS-LXI3mujmwzI9_sTuvOcwP6YbBEj9mh3gzDClQE8f2IImGwEh4VHtBsS0ddy_GlDHVJjwoU7uP-8DraUTHUEbiGztAvjdIA240tuVWQNMk44ZTy_2IHw4zGAv12IusB0wGrgjR6sc1DzLTBLpTqm5-w-uoZavL726MZdLkOKBNDUmjq6M85OME_cE-9KDCZRMwT5tKoDwyMEifQipI5dBOW-GgrZTZTyY7o6JHfK4pEGsJry-4YTeELywAPHe8BrNi-r5" rel="nofollow" target="_blank">X</a>.</p>    <p><strong>Forward Looking Statements</strong><br></br>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the best-in-class potential of CGT1145, the company's JAK2 V617F mutant-selective inhibitor candidate; the potential for CGT1145 to address the underlying mutational driver of disease while mitigating off-target hematological effects; the potential for CGT1145 to eradicate JAK2 V617F myeloproliferative neoplasm propagating cells and induce molecular remission with improved hematologic tolerability; and the company's plan to submit an IND in 2026 for CGT1145. The use of words such as, but not limited to, &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;might,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; or &#34;would&#34; and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption &#34;Risk Factors&#34; in Cogent&#39;s most recent Annual Report on Form 10-K, as supplemented by Quarterly Reports on Form 10-Q and other filings Cogent makes with the SEC from time to time . Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc0NTkxOCM3NjU4NTY1IzIwODUxMjc="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/M2YxZjlmZjMtNTc5Yy00ZDRkLWJiYTEtMjE4YmVjYTY0ZWIwLTEwOTY2OTgtMjAyNi0wNi0xMi1lbg==/tiny/Cogent-Biosciences-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><pre>Contact:
Christi Waarich
Senior Director, Investor Relations
<a href="mailto:christi.waarich@cogentbio.com">christi.waarich@cogentbio.com</a>
617-830-1653</pre><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/2b8cbfab-a4de-4e17-bdd6-7ef597a95d2e"><img src="https://ml.globenewswire.com/media/2b8cbfab-a4de-4e17-bdd6-7ef597a95d2e/small/cogent-biosciences-logo-rgb-png.png" border="0" width="150" height="62" alt="Primary Logo"></img></a></p>

Cogent presented CGT1145 preclinical data at EHA, highlighting >100x selectivity over JAK2 WT and JAK1/3, plus strong oral bioavailability. The company aims for IND in 2026, signaling a potential disease-modifying JAK2 therapy for MPNs with better tolerability. Clinical proof remains years away, so risk remains high.

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News